Medrol

Methylprednisolone, the active ingredient in Medrol, is a corticosteroid presented as an oral tablet for systemic use. It reduces inflammation and modulates immune responses, and is prescribed for a range of inflammatory, allergic, autoimmune and rheumatic conditions in adult patients.

GNH USA supplies Medrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global healthcare providers.

Medrol is a glucocorticoid that acts on inflammatory and immune pathways to control disease activity. - Asthma exacerbations: reduces airway inflammation and improves breathing. - Rheumatoid arthritis: alleviates joint inflammation and pain. - Systemic lupus erythematosus: suppresses immune activity to control disease flares. - Severe allergic reactions: diminishes swelling, hives and other hypersensitivity symptoms. - Dermatologic inflammatory conditions (e.g., eczema): decreases skin inflammation and itching.

Common Side Effects: - Increased appetite and weight gain. - Insomnia or difficulty sleeping. - Mood changes, including irritability. - Elevated blood glucose levels. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Adrenal insufficiency on abrupt discontinuation. - Severe infections due to immunosuppression. - Osteoporosis or bone fractures with long‑term use. - Cataracts or glaucoma. - Psychosis or severe mood disturbances. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy, consider the following safety measures. - Assess for active infection: postpone treatment if uncontrolled. - Monitor blood glucose: especially in diabetic patients. - Screen for osteoporosis: consider bone‑protective strategies. - Taper gradually: avoid abrupt discontinuation to prevent adrenal crisis. - Store at ambient temperature: keep in the original pack, protect from moisture.

Methylprednisolone may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce steroid efficacy. - Live vaccines: increased risk of infection. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding risk. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - Diabetic agents: potential for altered glucose control.